Skip to main content

Mexico Medical Device Regulation

RAPath Mexico is a plain-English reference guide to medical device regulation in Mexico, covering the full device lifecycle under COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) — Mexico's federal health authority.

Regulatory authority

COFEPRIS operates as a division of Mexico's Ministry of Health (Secretaría de Salud / SSA). It governs device classification, market authorisation, quality system requirements, post-market surveillance, and enforcement for all medical devices placed on the Mexican market.

What this site covers

SectionWhat you'll find
Getting StartedFramework overview, who needs to comply, DIGIPRiS portal
Device ClassificationClass I · II · III, exemption annexes, IVD & SaMD
Pre-MarketStandard route, equivalency route, dossier, timelines
Mexico Registration HolderMRH obligations, appointing, changing holders
Post-MarketTechnovigilance, NOM-240, renewals, labelling
Quality System (NOM-241)GMP requirements, ISO 13485 equivalency, inspections
Legislation & NOMsLey General de Salud, Reglamento Insumos, NOM tracker
Digital Health & SaMDSoftware, AI/ML, mobile health apps
Special AccessCompassionate use, clinical investigations
InternationalIMDRF, PANDRH, MDSAP, multi-market strategy
ResourcesLinks, DIGIPRiS guide, fees, forms

The regulatory framework at a glance

Mexico's medical device regulatory system rests on three tiers:

  1. Ley General de Salud (General Health Law) — the primary federal legislation establishing COFEPRIS's mandate and the requirement for sanitary registration.
  2. Reglamento de Insumos para la Salud (Health Supplies Regulation) — detailed requirements for classification, registration, GMP, and post-market obligations.
  3. Normas Oficiales Mexicanas (NOMs) — mandatory technical standards covering GMP (NOM-241), labelling (NOM-137), and technovigilance (NOM-240).

Key 2024–2025 reforms

Mexico's regulatory framework has undergone significant modernisation:

  • September 2025 — Abbreviated (Equivalency) Route formally expanded to all IMDRF and MDSAP member authority approvals (FDA, Health Canada, CE Mark, TGA and more), with a 30-working-day target review.
  • July 2025 — New classification decree replaces 2011/2014 exemption agreements, introducing updated Annexes 1–3.
  • April 2025 — NOM-241-SSA1-2025 (GMP) entered into effect, replacing the 2021 version.
  • January 2026 — Subsequent registration renewals now eligible for periods of up to 10 years.

How to use this site

Each section follows the same structure: an overview page explains the concept and its legal basis, followed by topic pages with practical detail. Every page links back to the relevant NOM, Ley General de Salud article, or COFEPRIS decree.

Disclaimer

This site is a regulatory reference resource, not legal or regulatory affairs advice. Regulations change. Always verify requirements against the current text of the relevant NOM or COFEPRIS decree. For device-specific guidance, consult a qualified regulatory affairs professional.


Part of the RAPath suite — plain-English medical device regulatory reference for AU · EU · HC · SG · UK · US · MX.